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Abstract
Background: Abnormal invasive hemodynamics after transcatheter aortic valve
replacement (TAVR) is associated with poor survival; however, the mechanism is
unknown.
Hypothesis: Diastolic dysfunction will modify the association between invasive
hemodynamics postTAVR and mortality.
Methods: Patients with echocardiographic assessment of diastolic function and post-
TAVR invasive hemodynamic assessment were eligible for the present analysis. Dia-
stology was classified as normal or abnormal (Stages 1 to 3). The aorto-ventricular
index (AVi) was calculated as the difference between the aortic diastolic and the left
ventricular end-diastolic pressure divided by the heart rate. AVi was categorized as
abnormal (AVi < 0.5 mmHg/beats per minute) or normal (≥ 0.5 mmHg/beats per
minute).
Results: From 1339 TAVR patients, 390 were included in the final analysis. The mean
follow-up was 3.3 ± 1.7 years. Diastolic dysfunction was present in 70.9% of the
abnormal vs 55.1% of the normal AVi group (P < .001). All-cause mortality was 46%
in the abnormal vs 31% in the normal AVi group (P < .001). Adjusted hazard ratio
(HR) for AVi < 0.5 mmHg/beats per minute vs AVi ≥0.5 mmHg/beats per minute for
intermediate-term mortality was (HR = 1.5, 95% confidence interval [CI] 1.1 to 2.1,
P = .017). This association was the same among those with normal diastolic function
and those with diastolic dysfunction (P for interaction = .35).
Abbreviations: AVi, aorto-ventricular index; CI, confidence interval; HR, hazard ratio; TAVR, transcatheter aortic valve replacement.
Received: 15 July 2020 Revised: 17 August 2020 Accepted: 22 August 2020
DOI: 10.1002/clc.23457
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2020 The Authors. Clinical Cardiology published by Wiley Periodicals LLC.
1428 Clin Cardiol. 2020;43:1428–1434.wileyonlinelibrary.com/journal/clc
Conclusion: Diastolic dysfunction is prevalent among TAVR patients. Low AVi is an
independent predictor for poor intermediate-term survival, irrespective of co-morbid
diastolic dysfunction.
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1 | INTRODUCTION
Hemodynamic assessment was initially developed as a supplemen-
tal tool to assess for paravalvular aortic regurgitation after trans-
catheter aortic valve replacement (TAVR).1,2 In the current era,
which is characterized by a low prevalence of paravalvular aortic
regurgitation,3,4 abnormal hemodynamics has been associated
with excess intermediate-term mortality.5 The aorto-ventricular
index (AVi) simultaneously examines the aortic diastolic pressure,
left ventricular end-diastolic pressure, and heart rate. An abnormal
AVi (ie, < 0.5 mmHg/beats per minute) has been associated with
an increased hazard for intermediate-term mortality, independent
of significant paravalvular aortic regurgitation and other con-
founding variables; however, the role of diastolic dysfunction is
unclear. It is possible that the harmful association of abnormal AVi
could be modified after controlling for baseline diastolic dysfunc-
tion. Our hypothesis is that diastolic dysfunction will modify the
association between invasive hemodynamics postTAVR and late
mortality.
2 | MATERIALS AND METHODS
2.1 | Patient population
All patients undergoing TAVR at the University of Bern were con-
secutively enrolled in an institutional database that is part of the
Swiss TAVI Registry (clinicaltrials.gov, NCT01368250).6 For this
analysis we required that patients had a pre-operative echocardio-
gram that was evaluable for diastolic dysfunction and invasive
hemodynamic assessment was performed after TAVR. Patients with
a history of atrial fibrillation, previous permanent pacemaker
implantation, mitral annular calcification, previous mitral valve
replacement, and moderate to severe paravalvular aortic regurgita-
tion were excluded.
The local ethics committee approved this study. All study par-
ticipants gave written informed consent. Baseline variables and
clinical follow-up data were collected and recorded prospectively.
Diastolic dysfunction data was re-evaluated in the Core lab by
reviewers blinded to clinical outcomes and retrospectively
entered in the database. Data was entered in an online database
held at the Clinical Trial Unit at the University of Bern,
Switzerland.
2.2 | Assessment of left ventricular diastolic
function
All patients underwent a transthoracic echocardiogram within 3 months
before TAVR. During the echocardiogram, at least three consecutive heart
beats were recorded and averaged for each parameter. Echocardiogram
loop and still frames were analyzed at a workstation for offline analysis
(Syngo Dynamics Workplace, version 9.5, Siemens Medical Solutions, Inc.,
Malvern, Pennsylvania). According to current American Society of Echo-
cardiography and European Association of Cardiovascular Imaging guide-
lines, the following variables were required for assessment of diastolic
dysfunction (see flow diagram from previous publication): (a) annular e'
velocity (septal e' < 7 cm/s or lateral e' < 10 cm/s); (b) average E/e'
ratio > 14; (c) left atrial maximum volume index >34 mL/m2; and (d) peak
tricuspid regurgitation velocity > 2.8 m/s.7 See flow diagram from previ-
ous publication for detailed description of assessment and gradient of dia-
stolic dysfunction.8 Left ventricular diastolic dysfunction was present if
three or more of the parameters were abnormal. In patients with left ven-
tricular diastolic dysfunction, the variables for categorizing severity of left
ventricular diastolic dysfunction were mitral flow velocities (E/A ratio and
peak E velocity). Grade 1 was defined as an E/A ratio ≤ 0.8 with a peak E
velocity of ≤0.5 m/s. Grade 3 was defined as an E/A ratio ≥ 2, with an ele-
vation of the mean left atrial pressure. When the E/A ratio was ≤0.8 and
the peak E velocity was >0.5 m/s, or if the E/A ratio was >0.8 to <2, the
following were considered: (a) peak continuous-wave Doppler velocity of
the tricuspid regurgitation jet obtained from multiple views; (b) E/e' ratio;
and (c) maximal left atrial volume index. If two or more of the available
parameters were abnormal, diastolic dysfunction was categorized as
Grade 2. If zero or one of the parameters were abnormal, Grade 1 diastolic
dysfunction was present. If only one parameter was available, the diastolic
dysfunction grade could not be reported. Diastolic dysfunction was also
not reported if there was a discrepancy between the two available param-
eters. However, if neither of the two available parameters were abnormal,
diastolic dysfunction was categorized as Grade 1, whereas Grade 2 dia-
stolic dysfunction was present if both parameters were abnormal. Patients
with normal diastolic function were classified as Stage 0.
2.3 | Procedure and assessment of invasive
hemodynamics
A multidisciplinary heart team of cardiac surgeons, interventional car-
diologists, imaging, and heart failure specialists decided on treatment
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strategy and suitability for TAVR, which was performed according
to current guidelines and standard approaches.9,10 Five to
10 minutes after valve implant, a single lumen pigtail catheter was
advanced into the left ventricle, while a second single lumen pigtail
catheter was placed in the ascending aorta. Both catheters were
flushed and zeroed. During stable rhythm and at end-expiration,
aortic pressure, left-ventricular pressure, and heart rate were
recorded. AVi was defined as the aortic diastolic pressure minus the
left-ventricular end-diastolic pressure divided by heart rate. AVi was
categorized as <0.5 mmHg/beats per minute (ie, abnormal hemody-
namics) and ≥ 0.5 mmHg/beats per minute (ie, normal hemodynam-
ics).5 Total arterial compliance was defined as stroke volume index
divided by aortic pulse pressure.11 The stroke volume index was
obtained from the pre-operative echocardiogram, while the aortic
pulse pressure was obtained by invasive pressures after valve
implantation.
After the intervention, all patients were monitored for at least
48 hours. Laboratory examination and a 12-lead electrocardiogram
were routinely performed immediately after the procedure and daily
thereafter. In all patients, echocardiogram was performed before
discharge.
2.4 | Clinical follow-up and endpoint assessment
Standardized clinical follow-up was performed at 30 days, 1 year,
and 5 years after TAVR. Telephone interviews, documentation
from referring physicians, and hospital discharge summaries
were used to ascertain clinical endpoints. All suspected adverse
events were independently adjudicated according to the criteria
by the valve academic research consortium-2.12 The primary
endpoint was all-cause mortality up to 5 years after TAVR. Sec-
ondary endpoints included cardiovascular death, and major
adverse cardiac and cerebrovascular events (MACCE). MACCE
was defined as all-cause mortality, myocardial infarction, or dis-
abling stroke.
2.5 | Statistical analysis
Continuous data are reported as mean ± SD and categorical variables
as the number of patients and percentage. P values were derived from
student's t tests for continuous and chi-square tests for categorical
variables comparing the two groups. The cumulative incidence of the
primary and secondary endpoints was estimated by the Kaplan-Meier
method. Patients were censored at the event of interest, time of last
contact, or the maximal follow-up time. Cox regression was used to
compare time-to-event data between groups. Crude hazard ratios
(HR) were generated with (95% confidence intervals [CIs]) with
P values from Wald chi-square tests. Adjusted HR (95% CI) included
all variables with a P value <.10 from the univariable analysis into the
multivariable model.
All analyses were performed with Stata version 14.2 (StataCorp,
College Station, Texas). Two-sided P values <.05 were considered sta-
tistically significant.
3 | RESULTS
Between August 2007 and December 2015, 1339 patients were
enrolled in the TAVI registry. Seven hundred and seventy underwent
detailed echocardiographic assessment and after excluding an addi-
tional 387 patients due to inability to grade diastolic dysfunction, lack
of postTAVR invasive assessment, or moderate to severe paravalvular
aortic regurgitation, 390 were included in the final cohort (Figure S1).
The mean follow-up was 3.3 ± 1.7 years.
One hundred and eighty-nine patients (48.5%) were categorized as
abnormal (AVi < 0.5) and 201 patients (51.5%) as normal (AVi > 0.5).
There were no differences in baseline characteristics, except that the
abnormal hemodynamics group had a higher prevalence of peripheral vas-
cular disease and higher estimated surgical risk (Table 1). Transfemoral
access was used in 99% overall, while conscious sedation was used in
77.2% of the abnormal vs 92.0% of the normal group (P < .001, Table 2).
The overall mean AVi was 0.52 ± 0.2 mmHg/beats per minute; 0.34
± 0.2 mmHg/beats per minute in the abnormal hemodynamics group, and
0.64 ± 0.2 mmHg/beats per minute in the normal hemodynamics group
(P < .001). Mean total arterial compliance was the same in both groups.
Intra-procedural hemodynamic variables are provided in Table 2.
Diastolic dysfunction was present in 70.9% of the abnormal AVi
group vs 55.1% of the normal AVi group (P < .001) (Table 3). Diastolic
dysfunction Stage 3 was present in 20.6% of the abnormal AVi group
vs 11.4% of the normal AVi group (P = .018).
All-cause mortality was 46% in the abnormal AVi group vs 31% in
the normal AVi group (P = .001) (Figure S2). After multivariable adjust-
ment, AVi < 0.5 was an independent predictor for intermediate-term
mortality (HR = 1.5, 95% CI 1.1 to 2.1; P = .017, Table 4). Complete
outcomes are provided in Table S1.
Among those with normal diastolic function, all-cause mortality was
27% in the AVi < 0.5 mmHg/beats per minute vs 29% in the AVi
≥0.5 mmHg/beats per minute group (P = .67). The multi-variable associa-
tion between low vs normal AVi was (HR = 1.06, 95% CI 0.45 to 2.50,
P = .89). Among those with diastolic dysfunction, all-cause mortality was
59% in the AVi < 0.5 vs 44% in the AVi ≥0.5 group (P = 0.006). The
multi-variable association between low vs normal AVi was (aHR = 1.90,
95% CI 1.10 to 3.60, P = .029; p for interaction = 0.35) (Figure 1).
We also categorized subjects according to normal estimated
baseline filling pressure (normal diastolic function and diastolic dys-
function Stage 1, which was present in 50.8% and elevated estimated
baseline filling pressure (diastolic dysfunction Stage 2 and 3, which
was present in 49.2%. Among those with normal baseline filling pres-
sures, the association between low vs normal AVi was (HR = 1.4, 95%
CI 0.76 to 3.6, P = .34) and among those with elevated baseline filling
pressures the association was (HR = 1.7, 95% CI 1.04 to 2.7, P = .033;
P for interaction = .32) (Figure 1).
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4 | DISCUSSION
The pertinent findings from the present analysis can be summarized
as follows: (a) Baseline diastolic dysfunction was prevalent among
TAVR patients. (b) Postimplantation AVi < 0.5 mmHg/beats per
minute was an independent predictor for poor intermediate-term sur-
vival. (c) Abnormal invasive hemodynamics was associated with poor
prognosis irrespective of baseline diastolic dysfunction. We previously
theorized that each component of the AVi would have clinical signifi-
cance. For example, a low aortic diastolic pressure could represent
unrecognized paravalvular aortic regurgitation, poor systemic flow,
and/or poor arterial compliance. An elevated left ventricular end-
diastolic pressure could represent left ventricular systolic dysfunction
and/or diastolic dysfunction. An elevated heart rate could represent
TABLE 2 Procedural characteristics according to aorto-ventricular index category
Variable, n (%) AVi < 0.5 AVi ≥0.5 Total P value
Conscious sedation 146 (77.2) 185 (92.0) 331 (84.9) <.001
Transfemoral access 187 (98.9) 199 (99.0) 386 (99.0) .13
Valve type:
CoreValve 75 (39.7) 74 (37.2) 149 (38.2) .25
Sapien 3 45 (23.8) 62 (30.8) 107 (27.4)
Sapien XT 35 (18.5) 39 (19.6) 74 (19.0)
Evolut R 14 (7.4) 7 (3.5) 21 (5.4)
Lotus 13 (6.9) 17 (8.5) 30 (7.7)
Other valves 7 (3.7) 2 (1.0) 9 (2.3)
Postimplant hemodynamics:
Aortic systolic blood pressure, mmHg 129.4 ± 28.2 148.7 ± 27.4 139.3 ± 29.4 <.001
Aortic diastolic blood pressure, mmHg 50.1 ± 11.0 66.7 ± 14.1 58.6 ± 15.1 <.001
LVEDP, mmHg 25.5 ± 11.1 21.3 ± 8.2 23.3 ± 9.9 <.001
Heart rate, beats per minute 73.1 ± 16.4 67.4 ± 12.5 70.1 ± 14.8 <.001
AVi, mmHg/beat per minute 0.34 ± 0.2 0.68 ± 0.2 0.52 ± 0.2 <.001
Total arterial compliance 0.45 ± 0.2 0.45 ± 0.2 0.45 ± 0.2 .89
Note: AVi, aortoventricular index, reported as mmHg/beats per minute.
Abbreviations: AVi, aorto-ventricular index; LVEDP, left-ventricular end-diastolic pressure.
TABLE 1 Baseline characteristics according to aorto-ventricular index category
Variable, n (%) AVi < 0.5 (n = 189) AVi ≥0.5 (n = 201) Total (n = 390) P value
Age, mean years 81.6 ± 6.3 81.9 ± 5.8 81.7 ± 6.1 .58
Male sex 89 (47.1) 104 (51.7) 193 (49.5) .36
BMI, mean kg/m2 26.4 ± 4.9 26.4 ± 5.3 26.4 ± 5.1 .99
Diabetes mellitus 53 (28.0) 44 (21.9) 97 (24.9) .20
Hypercholesterolemia 120 (63.5) 124 (61.7) 244 (62.6) .75
Hypertension 162 (85.7) 167 (83.1) 329 (84.4) .49
Previous MI 37 (19.6) 26 (12.9) 63 (16.1) .10
Previous PCI 58 (30.7) 49 (24.4) 107 (27.4) .17
Previous CABG 29/184 (15.8) 19/196 (9.7) 48/380 (12.6) .09
Previous Stroke/TIA 17 (9.0) 18 (8.9) 35 (9.0) 1.00
PVD 26 (13.8) 14 (7.0) 40 (10.2) .03
COPD 23 (12.2) 23 (11.4) 46 (11.8) .88
Renal insufficiencya 135 (71.4) 143 (71.1) 278 (71.3) 1.00
Logistic Euro score, mean 22.2 ± 15.1 16.6 ± 11.1 19.4 ± 13.5 <.001
STS score, mean 6.5 ± 4.2 4.9 ± 2.8 5.7 ± 3.6 <.001
Note: AVi, aortoventricular index, reported as mmHg/beats per minute.
Abbreviations: AVi, aortoventricular index, BMI, body mass index, CABG, coronary artery bypass grafting, COPD, chronic obstructive pulmonary disease,
MI, myocardial infarction, PCI, percutaneous coronary intervention, PVD, peripheral vascular disease, TIA, transient ischemic attack.
aDefined as estimated glomerular filtration rate < 60 mL/minutes/m2.
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poor systemic flow (since heart rate is inversely related to stroke vol-
ume) and/or background medical therapy. Therefore, the AVi is more
than just an assessment of diastolic dysfunction, which was born out
in the study findings.
These findings confirm our previous observation of an association
between abnormal hemodynamics and poor survival, but this time in a
larger independent cohort. The current analysis leveraged the Bern
TAVI registry, which represents the largest published work on dia-
stology and TAVR. Diastolic dysfunction was prevalent among all
patients but especially among those with abnormal hemodynamics;
however, pre-operative diastolic dysfunction did not modify the asso-
ciation between abnormal AVi and intermediate-term survival. We
found no evidence for a difference in total arterial compliance
between groups, which was another potential mechanism for the haz-
ardous association.
Moderate to severe paravalvular aortic regurgitation has consis-
tently been shown to be associated with poor survival4,13-18;
therefore, we excluded these patients from analysis. The prognostic
significance of mild aortic regurgitation is not clear with some studies
revealing no association,4,19 and others revealing a hazardous associa-
tion.20 Our results to not apply to patients who have moderate to
severe paravalvular aortic regurgitation.
We previously reported that diastolic dysfunction Stage 3 was
the strongest predictor for 1 year mortality. Optimal management of
left ventricular diastolic dysfunction among TAVR patients is not well
known.21 Diastolic dysfunction remains the same in half or more of
patients 1 year after TAVR,8,22 and myocardial fibrosis remains
unchanged 9 months after surgical AVR.23 However, patients across
the spectrum of diastolic dysfunction have been shown to improve
health status as early as 1 month after TAVR.24 The mechanism for
the low AVi and excess mortality association remains unclear. Patients
with abnormal invasive hemodynamics may be more sensitive to vol-
ume overload from even mild paravalvular aortic regurgitation.25 It is
also possible that patients with abnormal hemodynamics are
TABLE 3 Preoperative echocardiography data according to aorto-ventricular index category
Variable AVi <0.5 AVi ≥0.5 Total P value
Left ventricular systolic function
Left ventricular ejection fraction, % 53.0 ± 16.1 (n = 178) 56.2 ± 13.5 (n = 192) 54.6 ± 14.8 (n = 370) .037
Stroke volume index, cc/beat/m2 31.8 ± 11.6 (n = 146) 34.2 ± 13.2 (n = 147) 33.0 ± 12.5 (n = 293) .09
Left ventricular diastolic function
E/A ratio 1.5 ± 1.1 (n = 183) 1.3 ± 1.0 (n = 197) 1.4 ± 1.1 (n = 380) .075
E wave, m/sec 0.95 ± 0.40 (n = 182) 0.80 ± 0.31 (n = 197) 0.90 ± 0.36 (n = 379) <.001
A wave, m/sec 0.87 ± 0.42 (n = 182) 0.82 ± 0.34 (n = 197) 0.84 ± 0.38 (n = 379) .21
E/e' ratio 23.6 ± 11.9 (102) 19.7 ± 12.6 (n = 123) 21.5 ± 12.4 (n = 225) .02
e', cm/sec 4.5 ± 1.3 (n = 101) 4.6 ± 1.6 (n = 121) 4.5 ± 1.5 (n = 222) .74
Deceleration time, msec 223.6 ± 85.0 (n = 181) 241.6 ± 86.6 (n = 196) 232.9 ± 86.2 (n = 377) .043
Isovolumic relaxation time, msec 78.2 ± 23.5 (n = 177) 81.1 ± 22.6 (n = 194) 79.7 ± 23 (n = 371) .23
Tricuspid regurgitation velocity, m/sec 2.9 ± 0.6 (n = 129) 2.8 ± 0.5 (n = 121) 2.8 ± 0.5 (n = 250) .08
Left atrial volume index, mL/m2 44.6 ± 17.1 (n = 183) 41.3 ± 17.1 (n = 198) 42.9 ± 17.1 (n = 381) .065
Diastolic dysfunction Stage:
0 55 (29.1%) 90 (44.8%) 145 (37.2%) .002
1 26 (13.8%) 27 (13.4%) 53 (13.6%) 1.00
2 69 (36.5%) 61 (30.3%) 130 (33.3%) .20
3 39 (20.6%) 23 (11.4%) 62 (15.9%) .018
Valvular regurgitation
Aortic regurgitation ≥ moderate 4/70 (5.7%) 4/58 (7.0%) 8/128 (6.2%) 1.0
Mitral regurgitation ≥ moderate 32/187 (17.1%) 24/198 (12.1%) 56/385 (14.5%) .19
Tricuspid regurgitation ≥ moderate 27/187 (14.4%) 14/198 (7.1%) 41/385 (10.6%) .02
Aortic stenosis severity
Aortic valve area, cm2 0.76 ± 0.20 (n = 70) 0.76 ± 0.30 (n = 59) 0.76 ± 0.26 (n = 129) .97
Mean aortic valve gradient, mmHg 41.5 ± 20.4 (n = 167) 43.2 ± 17.3 (n = 173) 42.3 ± 18.9 (n = 340) .41
Left ventricular hypertrophy
Relative wall thickness 0.53 ± 0.2 (n = 160) 0.54 ± 0.2 (n = 169) 0.53 ± 0.5 (n = 329) .60
LV mass index, g/m2 144.2 ± 52.7 (n = 162) 140.0 ± 51.7 (n = 175) 142 ± 52.2 (n = 337) .47
Note: AVi, aortoventricular index, reported as mmHg/beats per minute.
Abbreviations: AVi, aorto-ventricular index; EF, ejection fraction; LV, left ventricular.
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particularly sensitive to heart rate, blood pressure, and filling pres-
sures, which could be influenced by background medical therapy. It is
also possible that infiltrative myocardial disease processes such as car-
diac amyloidosis could be prevalent in some of the patients with
abnormal hemodynamics.26,27
Limitations of the current analysis include: (a) Abnormal hemody-
namics was present in approximately one-fifth of our derivation
cohort vs approximately one-half of patients in the current cohort.
The reason for this difference is unknown. Aortic diastolic blood pres-
sure was the same between the two cohorts with abnormal hemody-
namics; however, the Bern TAVI registry was associated with a higher
left ventricular end-diastolic pressure and heart rate. This may reflect
differences in background/procedural medical therapy; however, this
information was not available in either registry. (b) Patients with mitral
annular calcification, atrial fibrillation, previous pacemaker or surgical
mitral valve were excluded from the current study. This could have
resulted in unintended selection bias; however, these characteristics
were included in our development cohort.5 (c) Residual confounding
cannot be excluded due to the observational nature, relatively modest
size of the database, and inability to perform propensity analysis. (d) It
is possible that poor prognosis from abnormal hemodynamics was
influenced by mild paravalvular aortic regurgitation. Although we
excluded patients with moderate to severe paravalvular aortic regurgi-
tation, we were unable to distinguish no/trivial/mild paravalvular aor-
tic regurgitation among the analyzed cohort. However, in our
development cohort, we excluded patients with mild paravalvular aor-
tic regurgitation and still noted a harmful association from abnormal
hemodynamics.5 (e) Total arterial compliance was calculated from
stroke volume index which was derived from pre-operative echocardi-
ography, while pulse pressure was obtained from intra-operative inva-
sive pressures. (f) We were unable to examine sub-groups with low
ejection fraction/low-gradient aortic stenosis.
5 | CONCLUSION
In summary, invasive hemodynamic assessment after TAVR can be
used to risk stratify patients. There was a high prevalence of diastolic
dysfunction among TAVR patients. AVi < 0.5 mmHg/beats per minute
was associated with poor intermediate-term survival, and baseline dia-
stolic dysfunction did not modify this association.
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